It’s very encouraging to see the FDA showing forward thinking when it comes to AI/ML-based diagnostics. Even the best model can be outdated quickly given the changing data landscape, making frameworks like Augusta that allow for model refinement and evolution to be crucial. We welcome this mindset as we work with our partners to build more interpretable and more adaptable diagnostic models.
Empowering healthcare and R&D innovation.
BioSymetrics has created the first biomedical specific machine learning framework and programming language to increase precision, shorten timelines, and improve discovery.
The Augusta™ software platform significantly improves time-to-market and drives innovation by bringing together automated pre-processing, management of disparate data, integrated analytics, feature engineering, and predictive modeling with Contingent AI in a single, easy-to-use framework.
Biopharma, Pharmaceutical, and CRO’s can rapidly leverage the power of AI and ML to enable lead compound discovery and trials. Easy to deploy, the Augusta™ framework enables faster pre-processing and model interrogation.
Utilize advanced artificial intelligence to classify subpopulations and tailor medical treatment to individual characteristics. The Augusta™ platform analyzes and draws inferences from vast amounts of data points, improving quality of patient care, enabling cost-effectiveness, reducing readmissions and mortality rates.
Hospitals, healthcare systems, and medical groups can improve institutional operations, finance and research programs. Applying machine learning (ML) to EMR’s, billing, admissions, radiology, cardiology, neurology, oncology and obstetrics (to name a few).
The AugustaTM platform allows rapid and effective integrated analytics and Machine Learning (ML) on many different kinds of biomedical and healthcare data types. Our AI ML platform capabilities include over 140 data modules that can be leveraged in data science and predictive analytics initiatives.
We offer turnkey services to our clients and corporate partners, with the aim of assisting organizations and teams in getting the greatest benefit from their data science initiatives. Our track record in massive data analytics including machine learning has been recognized with industry awards and conference speaking opportunities, and ties to our insight and knowledge base about the complexities in biomedical AI.
BioSymetrics services are available in several different ways, from our comprehensive technology solution implementations formalized in licensing agreements, to CRO consulting engagements and ad hoc projects.
But don’t know what it means?
In any data science pipeline there are a number of options that are selected for data processing (e.g. contrast settings for medical images, data imputation approaches, bandpass filter cut-offs for ecg signals). Typically, these options are selected manually based on previous experience of the Data Scientist or recommendations from previous, similar studies. In contingent AI, any “settable” parameter for data processing, data integration, or feature selection is permuted and the corresponding effects on the downstream predictive model measured. This process is similar to hyperparameter tuning in machine learning, however instead of optimizing only the machine learning model, the entire data science pipeline (including model selection) is subject to optimization.
Advocate for healthcare technology innovation joins BioSymetrics in a mission to empower the application of AI within biomedicine.
NEW YORK, February 7, 2019 (GLOBE NEWSWIRE) – BioSymetrics, an artificial intelligence and machine learning SaaS company, announces Dr. Calum MacRae as Senior Advisor. Dr. MacRae is an innovative pioneer in genetics, biology, and drug discovery. With his deep knowledge and expertise, Dr. MacRae will assist BioSymetrics in the design and application of the company’s software for use in drug discovery, precision medicine and health systems.
“The introduction of AI into medicine is challenged by a fundamental defect of information content and standards,” said Dr. Calum MacRae. “BioSymetrics is leading the promise that we are entering an era in which precision medicine and AI finally attain real world applications; overcoming a number of AI challenges across a wide spectrum of biomedicine.” Read More